Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Neuroendocrine Cancer

Department of Health written question – answered on 7th June 2016.

Alert me about debates like this

Photo of Nick Brown Nick Brown Chair, Finance Committee (Commons)

To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.

Number of patients treated in 2011/121

Number of patients treated in 2012/131

Number of CDF notifications 2013/142

Number of CDF notifications 2014/152

Number of CDF notifications 2015/16 (to Sept) 2

Peptide receptor radionuclide therapy (to include Lutetium-177 or Yttrium-90 octreotide analogues)

49

117

152

229

116

1 Source: Strategic Health Authority returns to the Department of Health

2 Source: NHS England

Information on the number of peptide receptor radionuclide therapy treatments provided outside of the CDF is not collected.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.